- MustGrow study conducted by third-party lab reports 100% control of ravaging disease
- Fusarium wilt TR4 has devastated $25-billion global banana industry
- Next step in testing will evaluate patented biopesticide technology in additional lab and field settings
MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has released potentially industry-changing results for its initial Colombia laboratory test evaluating the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, which was conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reports 100% control of the disease (https://ibn.fm/XhRSH).
Sometimes called the Panama disease, Fusarium wilt TR4 has devastated the $25-billion global banana industry, reaching a point where the Colombian government actually declared a state of emergency. The lab results indicate a “unique feat — a feat MustGrow believes no other agri-science team has achieved”: controlling Fusarium wilt TR4 definitively…
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.